This seaweed extract outperforms COVID-19 drug remdesivir in the lab

{ object.primary_image.title }}

And it could be used to develop preventive treatments. Remdesivir was the first major pharmaceutical breakthrough of the coronavirus pandemic: Research has found it’s able to help some patients recover faster from severe cases of the illness and may make it more likely that they survive. But a new study suggests that an extract from seaweed may outperform the drug. Read Full Story

Read Full Article on Fast Company

Oleandrin, Trump’s latest hope for a COVID-19 miracle cure, is a deadly plant poison

{ object.primary_image.title }}

An extract from the plant may have performed well in the lab, but do not eat the flower in an attempt to get virus-preventing benefits: It’s responsible for cases of accidental poisoning across the globe every year. With COVID-19 cases and deaths rising in the U.S. and globally, identifying new therapies to prevent and combat the virus is a top priority. Natural products from plants are an attractive option in the search for a cure. Approximately 374,000 plant species are on Earth; humans have used more than 28,000 of them as a form of medicine. Read Full Story

More

More Evidence Emerges That Host-Read Podcast Ads Outperform Others

{ object.primary_image.title }}

Host-read podcast ads outperform non-host-read ads on brand recall as well as other key marketing metrics, according to recent data from Nielsen. Sourced from more than 260 Nielsen surveys, the new figures explore the importance of podcast ad type. Here’s a roundup of the results as well as some key insights into podcast ads from… Read More » The post More Evidence Emerges That Host-Read Podcast Ads Outperform Others appeared first on Marketing Charts .

More

How TB Alliance’s Mel Spigelman created a promising new anti-tuberculosis drug

{ object.primary_image.title }}

For demonstrating how a nonprofit can develop drugs as well as Big Pharma can, Mel Spigelman is one of Fast Company’s Most Creative People in Business for 2020 In August 2019, TB Alliance’s pretomanid became one of three new anti-tuberculosis drugs approved by the FDA, and the first developed and registered by a nonprofit. When internist Mel Spigelman joined the organization (a product-development partnership, or PDP) as its head of R&D, in 2003, drug-resistant TB was an emerging public health priority, with an estimated 300,000 new cases per year worldwide. TB Alliance had recently licensed rights to develop a promising new drug from the biotech company Chiron. Spigelman jump-started its development, hiring a team with “expertise from early discovery through registration,” he says. “I wanted to be on a basis of equals with drug-development partners” such as Mylan and GlaxoSmithKline, which would enable the organization to move projects forward more …

More

Can Biden do more than just undoing Trump’s anti-immigration legacy?

{ object.primary_image.title }}

A backlash from Trump—and a need for essential workers—may create the urgency for Biden to push for real immigration reform, not just administrative fixes. It’s now an image forever etched into the history of America: Donald Trump descending the gold escalator of his Fifth Avenue hotel to announce his candidacy for president. The words he delivered after would be just as long-lasting. “When Mexico sends its people, they’re not sending their best,” he famously spouted, not even two minutes into his 45-minute campaign launch speech . “They’re bringing drugs. They’re bringing crime. They’re rapists. And some, I assume, are good people.” It was evident from the very start that Donald Trump’s presidency was founded on anti-immigrant sentiment. Read Full Story

More

Subscribe to our newsletter

Join our newsletter and never miss out trending marketing news.

HitcountVariables(pk=6335, ajax_url='/api/hit/ajax/', hits='2')